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SIGNIFICANCE
Superficial cryotherapy is one of the most commonly used 
treatment modalities for keloid scars; however, its mole-
cular mechanism is still not completely understood. This 
study retrospectively evaluated the efficacy of combined 
treatment with cryotherapy and intralesional steroid injec-
tion or intralesional steroid injection in 40 patients. Clini-
cal scar improvement, especially improvement in redness 
of scars, was significantly greater when cryotherapy was 
combined. Histologically, abnormal collagen bundles and 
dermal vessels from cryotherapy-treated keloid tissue 
were significantly reduced. Moreover, CD163+ M2 macro-
phages and matrix metalloproteinase-9 were significantly 
increased. These data indicate that cryotherapy-recruited 
macropahges supply matrix metalloproteinase-9, which 
function in fibrotic resolution in during keloid treatment.
Cryotherapy is used to treat keloid scars; however, the 
molecular and pathological mechanisms are not clear-
ly understood. This study retrospectively evaluated 
the efficacy of combined treatment with cryotherapy 
and intralesional triamcinolone injection (Cryo+TA) 
or intralesional TA monotherapy (TA) in 40 Asian pa-
tients with keloid scars. Scar improvement was as-
sessed using the Vancouver Scar Scale and Global 
Improvement Scale. Clinical improvement in scars, 
especially reduced vascularity and redness, was sig-
nificantly greater in the Cryo+TA group than in the 
TA group. Cryotherapy-treated and untreated keloid 
tissue was collected from six patients for analysis. 
Histo logically, collagen bundles from cryotherapy-
treated keloid tissue were more fibrillar and abnormal 
thickness was reduced. Immunohistochemical stain-
ing showed a reduced number of dermal vessels af-
ter cryotherapy. Moreover, CD163+ M2 macrophages 
and matrix metalloproteinase-9 (MMP-9) were signifi-
cantly increased in cryotherapy-treated tissue. Double 
immunofluorescence staining revealed co-expression 
of CD163 and MMP-9. These data indicate that cryo-
therapy recruits tissue-remodelling M2 macrophages 
with accompanying MMP-9, suggesting that cryothera-
py-recruited M2 macrophages function in fibrotic reso-
lution during keloid treatment.
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Superficial cryotherapy is commonly used for the treat­ment of keloid scars, either as a monotherapy or in 
combination with other treatment modalities, such as in­
tralesional triamcinolone (TA). In spite of its documented 
efficacy, the mechanism by which cryotherapy reduces 
keloid formation remains unclear. Based on previous 
find ings, it is widely recognized that hypertrophic or 
keloid scars occur on burned skin, but not on frostbitten 
areas (1). It is hypothesized that although burning and 
frostbite can both lead to tissue necrosis, they induce 
the secretion of distinct types of proinflammatory medi­
ators, thereby promoting different responses by tissue 
fibroblasts (2).
Numerous previous randomized, controlled studies 
have evaluated the efficacy of various keloid treatment 
modalities (3–6). These have revealed that keloids re­
spond significantly better to the combined treatment of 
Cryo+TA, than to either TA or cryotherapy alone (7, 8). 
The combination of Cryo+TA promotes faster keloid tis­
sue destruction by inducing direct cell injury and vascular 
damage (9). In addition, immediate tissue oedema caused 
by cryotherapy results in the even distribution of the 
steroid, thereby augmenting the effect of intralesional TA 
(3). Despite these intriguing observations, the molecular 
basis underlying the efficacy of cryotherapy is still not 
completely understood. 
Recent studies in other organ systems, including those 
focused on liver fibrosis and cardiac wound healing after 
myocardial infarction, have shown that matrix metallo­
proteinase­9 (MMP­9) contributes to the resolution of 
fibrosis (10, 11). Specifically, these studies emphasized 
the role of macrophages in providing MMP­9 to the fi­
brotic lesion, which in turn, helps to drive the process of 
fibrillolysis. Macrophages are innate immune cells that 
display functional plasticity in the changing environment 
of scar development and are therefore recognized as es­
sential mediators of wound healing (12). In particular, 
many studies suggest that alternatively activated (M2) 
macrophages secrete anti­inflammatory signals, which 
function to regulate tissue remodelling in a healing 
wound (13, 14). In contrast, the classically activated (M1) 
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macrophages display a proinflammatory phenotype and 
are not involved in this process.
The role of macrophages and MMP­9 in the forma­
tion and resolution of keloid scars is controversial. A 
study postulated a pro­fibrotic role of M2 macrophages 
and MMP­9 during the formation of keloid scars (15). 
However, contradictory results have also been published, 
especially during the process of keloid scar treatment. 
For instance, Azzam et al. (16) reported that fractional 
ablative laser treatment in keloid scars induced a rise in 
the level of MMP­9, which contributed to degradation 
and remodelling of collagen bundles. The current retro­
spective observational study on Asian keloid patients 
aimed to compare clinical outcomes in those treated with 
Cryo+TA vs patients treated with TA monotherapy. More­
over, this study aimed to evaluate the tissue histopatho­
logical events that result from cryotherapy treatment, in 
order to obtain molecular evidence supporting role of 
M2 macrophages and MMP­9 in cryotherapy­induced 
tissue remodelling and fibrotic resolution. 
MATERIALS AND METHODS
Clinical retrospective cohort study
Study design. This study retrospectively evaluated 40 Asian pa­
tients with keloid who underwent scar treatment by experienced 
board­certified dermatologists in a single tertiary institution in 
Korea (Severance Hospital of Yonsei University Health System, 
Seoul). Electronic patient medical records were reviewed after 
approval by the Yonsei University College of Medicine Institu­
tional Review Board (IRB number 4­2017­0470). All included 
patients were initially advised to undergo Cryo+TA, based on the 
height of the scar greater than 2 mm, presence of symptoms, such 
as itching/pain, and persistent spreading in size. The retrospective 
study was designed with 2 groups of patients who chose to receive 
either TA or Cryo+TA after consultation about the treatment costs, 
prognosis and possible side­effects. Exclusion criteria included a 
history of isotretinoin and immunosuppressant use, pregnancy, and 
those who underwent concomitant skin resurfacing procedures or 
laser treatments.
For administration of combination therapy, all physicians used 
a specialized tool called the CryoPen (L&C BIO, Gyeonggi­do, 
Korea), a spray­type device that, due to a freezing point of −79°C, 
facilitates more selective treatment than the traditional cryogun 
method, with fewer adverse effects on adjacent normal tissues. 
Three 10­s freeze­thaw cycles were performed directly over the 
lesions, while freezing was continued until the entire surface of the 
lesion became evenly white. For thicker areas of the scar greater 
than 5 mm in height, the CryoPen was sprayed with intermittent 
direct contact with the lesion. Immediately after cryotherapy, an 
injection of 10­mg/ml TA was administered evenly throughout the 
lesion. The treatment regimen was repeated on a monthly basis, 
until the keloid scars showed cessation of growth in size, complete 
flattening, and absence of symptoms.
Clinical assessments. Digital photographs were obtained prior to 
each treatment session using identical camera settings and lighting 
conditions. Scars had been routinely evaluated at the clinic using 
the Vancouver Scar Scale (VSS) to record changes in pigmentation, 
pliability, height, and vascularity (scores are listed in Table SI1). 
The VSS along the treatment periods were retrospectively review­
ed from the subjects’ medical records on every visit. Meanwhile, 
2 independent board­certified dermatologists were provided with 
clinical photographs from the initial and final visits of each pa­
tient. They were then asked to assign scores on scar improvement 
for the patients using 5­point Global Improvement Scale (GIS): 
5 = very much improved, 4 = much improved, 3 = improved, 2 = no 
change, and 1 = worse.
Histological analysis of the effect of cryotherapy on keloid scar 
treatment
Tissue preparation. Keloid tissues (n = 6) were obtained from 
patients who had been previously scheduled for surgical excision 
at the Department of Plastic and Reconstructive Surgery, Yonsei 
University College of Medicine (their keloid characteristics are 
described in Table SII1). Tissues were obtained according to a 
protocol approved by the Yonsei Institutional Review Board (4­
2017­0259), and all patients provided written informed consent. 
Each keloid lesion was divided into a cryotherapy­treated area 
and an untreated control area. Superficial cryotherapy was then 
performed on the cryotherapy­treated area 2 weeks prior to the 
surgery, according to the protocol described above. Both cryoth­
erapy­treated and untreated keloid tissues were collected, and 
immunohistochemistry and western blot analysis were performed.
Histological analysis. Paraffin blocks containing surgically excised 
keloid tissues were cut into 4­μm thick sections, and these were 
deparaffinized and dehydrated using a xylene and ethanol series. 
Samples were stained with haematoxylin and eosin (H&E) and 
the Masson’s Trichrome (MT) Stain Kit (ab150686, Abcam, Cam­
bridge, MA, USA), according to the manufacturer’s instructions. 
Immunohistochemistry. Consecutively sectioned tissue samples 
from paraffin blocks were deparaffinized by xylene. Sections were 
soaking in descending alcohol. The tissue sections were boiled 
in citrate buffer (pH 6; Sigma­Aldrich, St Louis, MO, USA) for 
antigen retrieval. Samples were then incubated with 3% H2O2 on 
ice for 10 min, followed by a blocking step with 5% skim milk in 
Tris­buffered saline with tween 20 (TBS­T). Primary antibodies, 
including anti­MMP­9 (1:100, ab38898; Abcam), anti­CD68 
(1:500, ab213363; Abcam), anti­CD163 (1:500, ab156769; Ab­
cam), anti­iNOS (1:20, ab3523; Abcam), and anti­TIMP1 (1:1000, 
ab211926; Abcam) were applied to the samples, and these were 
incubated at 4°C overnight. CD68 is used as a marker for cells of 
the monocyte lineage including tissue macrophages; CD163 and 
iNOS were used as specific monocyte/macrophage marker for M2 
and M1 macrophages, respectively. Primary antibodies were detec­
ted using the ChemMate EnVision Detection Kit (K5007; DAKO, 
Carpinteria, CA, USA). The slides were incubated and developed 
with the secondary antibody for 30 min and 3,3­diaminobenzidine 
for 5 min, followed by counterstaining using Gill’s haematoxylin. 
Double immunofluorescence staining with CD163 and MMP­9 
was used to determine cell localization of MMP­9. The primary 
antibodies used were as follows: rabbit anti­MMP9 (1:1,000) and 
mouse anti­CD163 (1:100). After 24 h of co­incubation, sections 
were washed with PBS and incubated with secondary antibodies 
for 1 h. Then sections sealed with 50% glycerol were observed 
and photographed under fluorescence microscopy. Image analysis 
for the semi­quantitative measurements of immunohistochemistry­
stained keloid sections was performed using Image J software 
(National Institutes of Health, Bethesda, MD, USA). All analyses 
were performed on images (original magnification, 100×) genera­
ted from 5 tissue sections of each study group, and the mean data 
was used for statistical analysis. 
Western blot analysis. Tissue samples were homogenized using 
a mechanical TissueLyser II (QIAGEN, Hilden, Germany) with 
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RIPA buffer, and protein concentrations were determined using 
the BCA Protein Assay Kit (Sigma­Aldrich). Total protein (30 µg) 
was separated by 8% or 10% SDS­PAGE and then transferred to 
nitrocellulose blotting membranes (GE Healthcare, Dornstadt, 
Germany). Membranes were blocked in 5% skim milk and treated 
with the following primary antibodies for 17 h at 4°C: anti­β­actin 
(1:1000, SC­47778, Santa Cruz Biotechnology, Dallas, TX, USA), 
anti­CD68 (1:1000, ab213363; Abcam), anti­MMP­2 (1:1,000, 
#4022s; Cell Signaling Technology, Beverly, MA, USA), anti­
MMP­9 (1:1,000, #3852s; Cell Signaling Technology), and anti­
CD163 (1:1,000, ab156769; Abcam). Membranes were washed 
3 times with TBS­T and treated with the secondary antibodies, 
anti­mouse IgG (1:2,000, SC­2005; Santa Cruz Biotechnology) 
and anti­rabbit IgG (1:2,000, #7074S; Cell signaling Technology), 
for 2 h at room temperature. These were then washed 3 times with 
TBS­T and treated with a chemiluminescence (ECL) detection 
reagent (Ab Frontier, Seoul, Korea). The resulting bands were 
visualized and quantified using the LAS­4000 mini luminescence 
image analyser (Fujifilm Life Sciences, Tokyo, Japan).
Statistical analysis 
Data are shown as mean ± standard error of the mean (SEM) and 
were analysed for the retrospective cohort study using Student’s 
t­tests. Statistical differences for the histological study were de­
termined using a non­parametric Mann–Whitney U test. p < 0.001 
(***),  p < 0.01 (**), and p < 0.05 (*) were considered statistically 
significant. SPSS v. 23.0 (SPSS Inc., Chicago, IL, USA) was used 
for all statistical analyses. 
RESULTS
Patient information and demographic characteristics 
This study retrospectively identified patients with keloid 
scars who visited our dermatology clinic between Janu­
ary 2017 and January 2019 (Table I). The study included 
40 Asian patients (17 males, 23 females), all of whom had 
initially been recommended for combination treatment 
with Cryo+TA, based on the scar’s thickest height > 2 mm, 
presence of symptoms, and persistence in the spread of 
size. Twenty study patients subsequently chose to receive 
TA monotherapy. The mean number of clinic visits for 
all patients was 14.8 sessions (range 7–25 sessions) in 
monthly intervals. Comparison of the 2 treatment groups 
revealed that the mean number of visits was 12.7 ± 0.9 
for Cryo+TA and 16.3 ± 1.1 for TA (p = 0.023). Only 3 
patients from the Cryo+TA group and 4 from the TA 
group revisited the clinic for the one­year follow­up after 
the last treatment. Their medical records showed stable 
disease status without recurrence of active scar prolifera­
tion. The mean treatment period was 13.1 ± 0.9 months for 
Cryo+TA and 16.7 ± 1.0 months for TA (p = 0.017). Thus, 
both the number of visits and the duration of treatment 
were significantly greater for the TA group. No missing 
values were observed in this retrospective cohort study. 
No significant differences were found in age, sex, or 
Table I. Retrospective study patient demographics
TA mono-
therapy Cryo+TA p-value
Age, years, mean ± SEM 44.1 ± 3.7 43.8 ± 4.6 0.960
Sex, n 0.115
  Male 11 6
  Female 9 14
Location of scar, n 0.531
  Stretch-pronea 7 11
  Stretch-freeb 13 9
Number of treatments (sessions), mean ± SD 13.6 ± 1.0 9.1 ± 0.8 0.001
Duration of treatments (months), mean ± SD 16.7 ± 1.0 13.0 ± 0.8 0.009
aStretch-prone areas included in the study: chest, shoulder, forearm, lower 
extremities. bStretch-free areas included in the study: earlobe, head and neck, 
abdomen, buttock.
SEM: standard error of mean; TA: triamcinolone injection Cryo: cryotherapy. [AQ7]
Fig. 1. Photographic comparison of clinical outcomes in keloid patients administered combined treatment with cryotherapy and triamcinolone 
(Cryo+TA) or triamcinolone (TA) monotherapy. (a, c) Initial and (b, d) post-treatment photographs of patients in the Cryo+TA group. (e, g) Initial 
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anatomical site (stretch­prone, stretch­free) distributions 
between the study groups. 
Clinical improvement assessments 
Clinical improvement was assessed in all subjects 
using the VSS (see Table SIII1). The result showed 
that the mean change in total VSS after treatment for 
the Cryo+TA group was 4.65 ± 0.41, whereas the mean 
change in total VSS for the TA group was 2.95 ± 0.36 
(p = 0.003, Fig. 1, Table II). These data indicate a signifi­
cantly greater improvement in total VSS for the Cryo+TA 
group relative to the TA group. Scores from individual 
VSS subcategories (pigmentation, vascularity, pliability, 
and height) were then analysed and it was found that the 
mean change in vascularity score after treatment was 
significantly great er for Cryo+TA (1.95 ± 0.15) than for 
TA (0.05 ± 0.15; p < 0.001). In contrast, no significant 
differences in the observed improvements in pliability, 
height, and pigmentation between the Cryo+TA and the 
TA groups were detected (Table II). Scars from each treat­
ment group were also evaluated using the GIS. The mean 
GIS score was 4.05 ± 0.17 for Cryo+TA, and 3.35 ± 0.15 
for TA, indicating a significantly greater improvement 
for Cryo+TA (p = 0.004).
Histopathological analysis of collagen in keloid scars 
treated with cryotherapy 
The histological features of cryotherapy­treated keloid 
tissues and untreated controls were then using immuno­
histochemistry (IHC) and western blot analysis in 6 
surgically­excised keloid scars. Notably, H&E staining 
revealed excessive and abnormally thick bundles of 
collagen fibres in the upper to mid­dermis of untreated 
lesions (Fig. 2a, b). These thick bundles were rarely 
detected in cryotherapy­treated tissues; they appeared 
more fibrillar, and the thickness of the abnormal collagen 
bundles was largely reduced relative to the untreated 
lesion (Fig. 2d, e). Masson’s trichrome staining of the 
cryotherapy­treated tissue showed replacement of the 
dense and thick collagen bundles by fine and shallow 
collagen. This apparent reduction in collagen expression 
in response to cryotherapy treatment was also confirmed 
by the semi­quantitative measurement (p < 0.0001, Fig. 
Table II. Clinical improvement assessment of Vancouver Scar Scale 
(VSS) and Global Improvement Scale (GIS) between triamcinolone 




Mean ± SEM p-value
Improvement in VSS (VSSinitial-VSSpost)
  Total VSS 2.95 ± 0.36 4.65 ± 0.41 0.003
  Vascularity 0.05 ± 0.15 1.95 ± 0.15 < 0.001
  Pliability 2.00 ± 0.20 1.55 ± 0.18 0.111
  Height 0.90 ± 0.16 1.15 ± 0.16 0.287
GIS 3.35 ± 0.15 4.05 ± 0.17 0.004
SEM: standard error of mean. p-values in bold indicates p < 0.05.
Fig. 2. Histologic analysis of keloids treated with cryotherapy. Hematoxylin and eosin (H&E) staining of (a, b) untreated keloid shows thick bundles 
of collagen fibers (scale bar =1 mm in lower magnification and 200 μm in higher magnification). Cryotherapy-treated keloid (d, e) reveals replacement 
of abnormal collagen by fine collagen, as well as the infiltration of large round cells with elongated nuclei. Immunohistochemical staining (c, f) reveals 
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3a, b). Moreover, the reductions in the number of blood 
vessels and the dermal thickness of abnormal collagen 
(determined as the distance between the uppermost and 
the deepest portion of densely stained collagen) were 
measured between cryotherapy­untreated and cryo­
therapy­treated tissues (p < 0.01, Fig. 3c, d). These results 
correlate with the clinical improvement in the redness 
and height of keloid scars after Cryo+TA. 
Immunohistochemistry and western blot analysis 
revealed an increased number of M2 macrophages and 
elevated MMP-9 levels in cryotherapy-treated tissue 
Interestingly, H&E staining not only showed decreased 
collagen thickness in cryotherapy­treated tissue, but 
also revealed the infiltration of large round cells re­
sembling macrophages with lightly stained elongated 
nuclei in­between the fine collagen bundles. To identify 
these cells, IHC staining with anti­CD68 antibodies was 
performed, which confirmed that cryotherapy­treated 
regions of keloid scars are populated by infiltrating 
macrophages (Fig. 2c, f). These cells were also posi­
tively stained with anti­CD163 antibodies, indicating 
that they belonged to the M2­like macrophage subtype 
(Fig. 4a–d). The additional IHC staining with anti­iNOS 
antibodies (mark ers for M1 macrophages) and anti­
TIMP ­1 antibodies showed no significant difference 
between control and cryotherapy­treated tissues (data 
not shown). 
Immunostaining with antibodies to MMP­9 was 
performed and higher expression of positive brown 
staining was detected in the dermis of cryotherapy­
treated tissue compared with control (Fig. 4e–h). To 
further confirm these observations, semi­quantitative 
analysis was conducted, which showed that the levels 
of both CD163 (green) and MMP (red) are significantly 
increased in cryotherapy­treated tissue relative to con­
trol tissue (p < 0.0001). Double immunofluorescence 
staining reveal ed co­expression of CD163 and MMP­9, 
suggesting a fibrinolytic role of M2 macrophages by 
the production of MMP­9 (Fig. 4 k, 1). Total protein 
extracts from excised keloid tissue were also analysed 
by western blot and a consistent pattern was observed, 
with increased expression of CD68, CD163 and MMP­9 
in cryotherapy­treated vs control tissue (Fig. 5). 
DISCUSSION
Cryotherapy, combined with intralesional TA, is one of 
the traditional first­line treatments for treating keloid 
scars. Intralesional TA injection diminishes excessive 
collagen synthesis and inhibits the rapid growth of 
keloid fibroblasts (17). Moreover, corticosteroid also 
controls the exaggerated local inflammatory processes 
in wound healing, thereby preventing keloid formation 
(18). Cryotherapy prior to TA injection not only induces 
early flattening of the lesion via microvascular damage, 
which results from the thawing phase and consequent 
vessel thrombosis, but also causes slight tissue oedema, 
which allows even distribution of the injected steroid (3). 
In addition, direct cellular injury due to the formation 
Fig. 3. Masson’s trichrome staining shows 
decreased number of dermal vessels and 
thickened collagen bundle after cryotherapy. 
Masson’s trichrome staining of (a) cryotherapy-
untreated tissue and (b) cryotherapy-treated tissue 
(scale bar indicates 1 mm, orginical magnification x25). 
(c) Comparison on the number of dermal blood vessels 
and (d) the dermal thickness of abnormal collagen 
bundles on cryo (-) and cryo (+) keloid tissues (arrow 
heads point blood vessels; dotted lines indicate dermal 
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Fig. 4. Immunohistochemical staining reveals the infiltration of M2 macrophages and recruitment of MMP-9 after cryotherapy. CD163+ 
macrophages in (a, b) cryotherapy-untreated tissue shows few positive cells, as compared to (c, d) cryotherapy-treated keloid lesion (CD163 staining, 
orginical magnifications x25 and x100). MMP-9 immunoreactivity in (e, f) cryotherapy-untreated and (g, h) cryotherapy-treated tissue reveals increase in 
MMP-9 after cryotherapy (MMP-9 staining, scale bar indicates 1 mm in lower magnification and 200 µm in higher magnification, orginical magnifications 
x25 and x100). (i) Percentage of positive area of CD163 and (j) MMP-9 (**p < 0.01). Double immunofluorescence staining shows co-expression of CD 
163 (green) and MMP-9 (red) in (k) cryotherapy-untreated and (l) cryotherapy-treated tissues (scale bar indicates 50 µm, original magnification x50).
Fig. 5. Quantitative western blot analysis confirms increased expression of CD68, CD163, and matrix metalloproteinase-9 (MMP-9) in 
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of ice crystals, which remove water from the cell, also 
promotes subsequent tissue destruction. 
This retrospective study compared the efficacy of 
monthly Cryo+TA vs TA for the treatment of keloid 
scars in 40 Asian patients. Conventionally, TA injection 
is given every 2–6 weeks; in the current study the TA 
group received monthly TA monotherapy, as the patients 
showed keloids with active inflammatory borders, while 
displaying symptoms such as itching and pain. Clinically, 
significantly greater improvements in total VSS and GIS 
scores were detected for the Cryo+TA group compared 
with the TA group. In particular, reduction in erythema 
was significantly greater in the Cryo+TA group, possibly 
due to efficient microvascular injury from adjuvant cryo­
therapy. The subsequent histopathological analysis also 
revealed a decreased number of blood vessels and de­
creased dermal thickness of abnormal collagen, thereby 
supporting the clinical results. Because of the possible 
limitations of a retrospective cohort study design, future 
confirmation of this finding by means of a prospective, 
randomized study is advisable.
A previous controlled study on the effect of cryo­
therapy reported that spray­type cryotherapy was 
clinically ineffective as a monotherapy (19). Here, we 
speculate that these conflicting results are probably due 
not only to the use of cryotherapy in combination with 
intralesional TA in our study, but also possibly to the 
differences in how we used the CryoPen. Specifically, 
we performed 3 well­retained freeze­thaw cycles with 
the CryoPen. Freezing was conducted for 10 s above 
the lesion, until the entire surface of the lesion became 
evenly white. On thicker areas of the scars, the CryoPen 
was also sprayed with intermittent direct contact to the 
lesion. This method creates an instant negative pressure 
formed between the tip of CryoPen and the scar, causing 
the scar tissue to be pulled up so that the lesion is slightly 
detached from the bottom tissue, therefore loosening 
the fibrotic spaces. Moreover, the thawing phase was 
strictly maintained for multiple seconds until the lesion 
colour returned to normal, which could allow adequate 
microvascular injury, leading to hypoxia and consequent 
tissue reduction.
Although the physical mechanisms by which cryo­
therapy causes vascular injury and tissue destruction 
are well known, the molecular mechanisms underlying 
the fibrinolytic process are not completely understood. 
Matrix metalloproteinases (MMPs) are a family of 
zinc­dependent proteases that regulate ECM turnover 
by processing a wide range of ECM components, such 
as collagen (20). MMP­2 and MMP­9, in particular, are 
gelatinases that promote degradation of the ECM. Nota­
bly, recent studies on liver fibrosis showed that MMP­9 
produced by Kupffer cells, resident hepatic macrophages 
localized in the lumen of sinusoids, contributes to the 
resolution of liver fibrosis (11, 21, 22). Specifically, this 
study used an MMP9–/– animal model to demonstrate that 
MMP­9 plays a critical role in macrophage­mediated 
liver fibrillolysis (23). In addition, studies on cardiac 
wound healing after myocardial infarction also found 
that deletion of macrophage­derived MMP­9 resulted 
in increased collagen accumulation (10, 14, 23). Col­
lectively, these studies suggest that macrophage­derived 
MMPs contribute to ECM destruction in a broad range 
of fibrotic diseases. 
During tissue injury and healing, the changing envi­
ronment reshapes macrophage phenotypes and provides 
them with diverse functional properties in each phase of 
the wound healing process: inflammatory phase, prolife­
rative phase, and maturation phase (24). Distinct macro­
phage populations that function in tissue remodelling are 
believed to limit and reverse tissue fibrosis by digesting 
ECM deposits in the late phase of wound healing. The 
current study performed histological analysis of keloid 
tissues and found that CD163+ M2 macrophages and 
MMP­9 are both highly co­expressed in cryotherapy­
treated scars. This suggests that superficial cryotherapy 
may induce the selective recruitment of anti­fibrotic M2 
macrophages, which in turn, secrete MMP­9 to facilitate 
degradation of excessive collagen deposits in keloid 
scars. Further functional assays should be performed to 
further investigate the dynamic roles of macrophages in 
wound healing and fibrotic resolution processes. 
In conclusion, these data suggest that M2­like tissue­
remodelling macrophages may represent a key factor that 
orchestrates fibrotic resolution in cryotherapy­treated 
keloid scars. Although conventional intralesional TA 
monotherapy is the most convenient method for treating 
keloid scars, its exclusive use can result in frequent recur­
rence and high rates of complication. This retrospective 
study found that combining TA and cryotherapy resulted 
in greater efficacy, not only for reducing scar volume, 
but also for improving erythematous colour. We propose 
that uncovering the mechanism by which cryotherapy 
induces macrophages to switch to an M2­like phenotype 
may lead to novel therapeutics for reducing fibrosis in 
keloid scars.
The authors have no conflicts of interest to declare.
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